---
title: Targeting the tissue factor coagulation initiation complex prevents antiphospholipid
  antibody development
date: '2023-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38142429/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231225170640&v=2.18.0
source: Blood
description: Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid
  syndrome (APS) are a major cause for acquired thrombophilia, but specific interventions
  preventing autoimmune aPL development are an unmet clinical need. While autoimmune
  aPL cross-react with various coagulation regulatory proteins, lipid-reactive and
  COVID-19 patient-derived aPL recognize the endo-lysosomal phospholipid lysobisphosphatidic
  acid (LBPA) presented by the cell surface expressed endothelial protein C ...
disable_comments: true
---
Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) are a major cause for acquired thrombophilia, but specific interventions preventing autoimmune aPL development are an unmet clinical need. While autoimmune aPL cross-react with various coagulation regulatory proteins, lipid-reactive and COVID-19 patient-derived aPL recognize the endo-lysosomal phospholipid lysobisphosphatidic acid (LBPA) presented by the cell surface expressed endothelial protein C ...